Insulin and pentastarch for severe sepsis [7]

New England Journal of Medicine

Volumn 358, Issue 19, 2008, Pages 2072-2073

  Muller, Laurent ^a   Jaber, Samir ^b   Lefrant, Jean Yves ^a  

^a DEPARTMENT OF NEUROLOGY   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT; HETASTARCH;

HEART FAILURE; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; KIDNEY FAILURE; LETTER; NEPHROTOXICITY; PHYSICIAN; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; CRITICAL ILLNESS; FLUID THERAPY; MULTIMODALITY CANCER THERAPY; NOTE; SEPSIS; TREATMENT FAILURE; HEMODYNAMICS; METHODOLOGY;

COMBINED MODALITY THERAPY; CRITICAL ILLNESS; FLUID THERAPY; HETASTARCH; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE; SEPSIS; TREATMENT FAILURE; HEMODYNAMICS;

EID: 43249104127     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6.
2. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
3. Kheterpal S, Tremper KK, Englesbe MJ, et al. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology 2007;107:892-902.
4. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002;95:544-51.